CL2004000686A1 - Uso del clorhidrato de la base del principio activo 1-(n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-p iperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptan para preparar un medicamento u - Google Patents

Uso del clorhidrato de la base del principio activo 1-(n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-p iperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptan para preparar un medicamento u

Info

Publication number
CL2004000686A1
CL2004000686A1 CL200400686A CL2004000686A CL2004000686A1 CL 2004000686 A1 CL2004000686 A1 CL 2004000686A1 CL 200400686 A CL200400686 A CL 200400686A CL 2004000686 A CL2004000686 A CL 2004000686A CL 2004000686 A1 CL2004000686 A1 CL 2004000686A1
Authority
CL
Chile
Prior art keywords
tirosil
lisil
carbonil
dihidro
dibromo
Prior art date
Application number
CL200400686A
Other languages
English (en)
Inventor
Herni Rudolf Klaus Eberl Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2004000686A1 publication Critical patent/CL2004000686A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA EL TRATAMIENTO O LA PREVENCION DE DOLORES DE CABEZA, MIGRANA O UNA CEFALEA ACUMULADA, EN EL QUE EL PROCEDIMIENTO COMPRENDE LA ADMINISTRACION COMUN DE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DEL HIDROCLORURO DE LA BASE DEL PRINCIPIO ACTIVO 1-(N2-(3,5-DIBROMO-N-((4-(3,4-DIHIDRO-2(1H)-OXO-QUINAZOLIN-3-IL)-1-PIPERIDINIL-CARBONIL)-D-TIROSIL)-L-LISIL)-4-(4-PIPERIDIN)-PIPERAZINA (A) Y UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DEL PRINCIPIO ACTIVO CONTRA LA MIGRANA SUMATRIPTANO, O UNA DE SUS SALES FISIOLOGICAMENTE ACEPTABLES DEL MISMO, ASI COMO LA CORRESPONDIENTE COMPOSICION FARMACEUTICA Y SU PRODUCCION.
CL200400686A 2003-04-01 2004-03-30 Uso del clorhidrato de la base del principio activo 1-(n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-p iperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptan para preparar un medicamento u CL2004000686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10314617A DE10314617A1 (de) 2003-04-01 2003-04-01 Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne

Publications (1)

Publication Number Publication Date
CL2004000686A1 true CL2004000686A1 (es) 2005-02-04

Family

ID=32980861

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400686A CL2004000686A1 (es) 2003-04-01 2004-03-30 Uso del clorhidrato de la base del principio activo 1-(n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-p iperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptan para preparar un medicamento u

Country Status (9)

Country Link
EP (1) EP1631282A1 (es)
JP (1) JP2006522044A (es)
AR (1) AR043793A1 (es)
CA (1) CA2520930A1 (es)
CL (1) CL2004000686A1 (es)
DE (1) DE10314617A1 (es)
TW (1) TW200501956A (es)
UY (1) UY28251A1 (es)
WO (1) WO2004087134A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740175A1 (de) * 2004-04-20 2007-01-10 Boehringer Ingelheim International Gmbh Verwendung eines cgrp-antagonisten in kombination mit einem serotonin-wiederaufnahme-hemmer zur behandlung von migräne
EP2337566A1 (en) * 2008-10-22 2011-06-29 Novartis AG Combinations for the treatment of migraine
EP3416618A1 (en) 2016-02-19 2018-12-26 ZP Opco, Inc. Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
US11660264B2 (en) 2017-08-23 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
US11660265B2 (en) 2018-06-28 2023-05-30 Emergex USA Corporation Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096

Also Published As

Publication number Publication date
EP1631282A1 (de) 2006-03-08
DE10314617A1 (de) 2004-10-14
TW200501956A (en) 2005-01-16
WO2004087134A1 (de) 2004-10-14
CA2520930A1 (en) 2004-10-14
AR043793A1 (es) 2005-08-10
JP2006522044A (ja) 2006-09-28
UY28251A1 (es) 2004-11-08

Similar Documents

Publication Publication Date Title
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
AR065797A1 (es) Usos y derivados de 1-(2- (2,4- dimetilfenilsulfanil) fenil) piperazina
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
AR025055A1 (es) Composiciones farmaceuticas
NI200700068A (es) Clorhidrato de 4-[[4-[[4-(2-cianoetenil)-2,6- dimetilfenil]amino]-2- pirimidinil]amino] benzonitrilo
CL2004000409A1 (es) Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
BRPI0409516A (pt) composição, uso de uma composição e processo de melhora da penetração de um ativo farmacêutico
PE20120252A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
HRP20090471T1 (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
AR055838A1 (es) Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
BRPI0417858A (pt) composto, composição farmacêutica, e, uso de uma composição farmacêutica
UY27416A1 (es) Uso de bibn4096 en combinación con otros fármacos antimigranosos para el tratamiento de migrana
RS54293B1 (en) PHARMACEUTICAL COMBINATION
AR031679A1 (es) Una composicion farmaceutica
CL2009001328A1 (es) Compuestos derivados de 3-oxo-isoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno del dolor.
BRPI0518554A2 (pt) uso de um inibidor de pde3
CL2004000686A1 (es) Uso del clorhidrato de la base del principio activo 1-(n2-[3,5-dibromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-p iperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptan para preparar un medicamento u
UY29712A1 (es) Sal de derivado de piperidina, composición farmacéutica que la contiene y aplicaciones
CL2009001330A1 (es) Compuestos derivados de ciano-3-oxoisoindolin-1-carboxamida, moduladores del canal de sodio nav1,7; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de un trastorno de dolor.
ECSP078037A (es) Formulaciones farmacéuticas de liberación inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] micronizado, y sus sales